Thus, the pembrolizumab-based approach may be recognized as a relevant comparator in clinical trials with first-line KRAS-targeted therapy on KRAS-mutated NSCLC depending on the efficacious outcomes in immunotherapy despite the KRAS mutational situation in this trial [141]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.